Element Materials Technology launched an integrated offering for its pharmaceutical services. The strategic initiative brings together the capabilities of its recent North American acquisitions of Nanosyn and JMI labs into its existing life sciences business. This integration creates a team of over 1,400 scientists and chemists operating across a worldwide network of laboratories.

Combining the contract development and manufacturing organization (CDMO) and contract research organizations (CRO) allows Element to support its customers at every stage of their product's life cycle. The large team combines extensive knowledge in scientific and regulatory fields with a wide selection of advanced equipment and  solutions.

Nanosyn has a track record of advancing small molecules from initial hits to investigational new drugs (IND), supported by a team of over 50 scientists equipped with cutting-edge technology and efficient operations.

Nanosyn’s laboratory in Santa Clara specializes in chemistry and drug discovery services, housing one of the largest chemical inventories of any pharmaceutical synthesis lab in the U.S. The company’s Santa Rosa lab is an FDA-inspected kilo lab facility, offering manufacturing capabilities across 6 GMP suites and 2 class 10,000 clean rooms, alongside state-of-the-art R&D facilities.

Furthermore, Element has established a market leading CRO based in North Liberty, Iowa, previously known as JMI Laboratories. The CRO has a proprietary SENTRY antimicrobial surveillance program, which plays a vital role in FDA regulatory submissions and new drug applications. With a team of over 70 professionals, the CRO meets Clinical Laboratory Improvement Amendments Act 1988 and is CLIA certified for clinical trials with capacity to conduct good laboratory practice (GLP) studies, enabling complete lab-to-market product support for customers through drug development, molecular testing, clinical trials, medical writing, and surveillance services.

Marie Keeley, vice president life sciences America at Element, said, “Pharmaceutical companies face a myriad of challenges in their pursuit of developing new products. The industry contends with supply chain disruptions, escalating development costs, staffing constraints, and manufacturing delays, making the process of bringing a new drug to market more demanding than ever before.”